Notes Receivable and Other Long-term Receivables (Narrative) (Detail) (USD $)	0 Months Ended	3 Months Ended		6 Months Ended					0 Months Ended	3 Months Ended			0 Months Ended			0 Months Ended				0 Months Ended		3 Months Ended						1 Months Ended				1 Months Ended	3 Months Ended		0 Months Ended	1 Months Ended		6 Months Ended			0 Months Ended				0 Months Ended	1 Months Ended	3 Months Ended		6 Months Ended			58 Months Ended	0 Months Ended				3 Months Ended
	Oct. 31, 2013	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2014	Jun. 30, 2013	Feb. 06, 2014	Jun. 30, 2014 Wellstat Diagnostics [Member]	Aug. 15, 2013 Wellstat Diagnostics [Member]	Jul. 31, 2012 Merus Labs [Member]	Jun. 30, 2014 Merus Labs [Member]	Dec. 31, 2012 Merus Labs [Member]	Sep. 24, 2013 Merus Labs [Member]	Sep. 30, 2013 AxoGen [Member]	Jun. 30, 2014 AxoGen [Member]	Aug. 14, 2013 AxoGen [Member]	Oct. 03, 2013 LENSAR [Member]	Nov. 02, 2013 Durata [Member]	May 27, 2014 Durata [Member]	Oct. 31, 2013 Durata [Member]	Nov. 05, 2013 DirectFlow [Member]	Nov. 06, 2013 DirectFlow [Member]	Jun. 30, 2014 Paradigm Spine [Member]	Feb. 14, 2014 Paradigm Spine [Member]	Mar. 05, 2014 Hyperion [Member]	Mar. 05, 2013 Hyperion [Member]	Jan. 27, 2012 Hyperion [Member]	Apr. 01, 2014 kaleo Note Receivable [Member]	Mar. 31, 2012 Notes Receivable [Member] Wellstat Diagnostics [Member]	Jun. 30, 2014 Notes Receivable [Member] Wellstat Diagnostics [Member]	Aug. 31, 2012 Notes Receivable [Member] Wellstat Diagnostics [Member]	Jul. 31, 2012 Notes Receivable [Member] Merus Labs [Member]	Apr. 30, 2013 Notes Receivable [Member] Avinger [Member]	Jun. 30, 2014 Notes Receivable [Member] Avinger [Member]	Apr. 18, 2013 Notes Receivable [Member] Avinger [Member]	Aug. 15, 2013 Credit Agreement [Member] Wellstat Diagnostics [Member]	Feb. 28, 2013 Credit Agreement [Member] Wellstat Diagnostics [Member]	Jan. 31, 2013 Credit Agreement [Member] Wellstat Diagnostics [Member]	Jun. 30, 2014 Credit Agreement [Member] Wellstat Diagnostics [Member]	Nov. 02, 2012 Credit Agreement [Member] Wellstat Diagnostics [Member]	Jul. 31, 2012 Credit Agreement [Member] Merus Labs [Member]	Aug. 15, 2013 Initial Loan [Member] Wellstat Diagnostics [Member]	Jun. 30, 2014 Initial Loan [Member] Merus Labs [Member]	Jun. 28, 2013 Additional Loan [Member] Wellstat Diagnostics [Member]	Jun. 30, 2014 Additional Loan [Member] Merus Labs [Member]	Oct. 03, 2013 Additional Loan [Member] LENSAR [Member]	Oct. 31, 2012 Royalty Agreement [Member] AxoGen [Member]	Jun. 30, 2014 Royalty Agreement [Member] AxoGen [Member]	Jun. 30, 2013 Royalty Agreement [Member] AxoGen [Member]	Jun. 30, 2014 Royalty Agreement [Member] AxoGen [Member]	Jun. 30, 2013 Royalty Agreement [Member] AxoGen [Member]	Dec. 31, 2013 Royalty Agreement [Member] AxoGen [Member]	Apr. 30, 2018 Royalty Agreement [Member] Avinger [Member]	Aug. 15, 2013 Term loan and interest [Member] Wellstat Diagnostics [Member]	Aug. 15, 2013 Forbearance principal and interest [Member] Wellstat Diagnostics [Member]	Oct. 31, 2013 Tranche two [Member] Durata [Member]	Nov. 06, 2013 Tranche two [Member] DirectFlow [Member]	Jun. 30, 2014 Tranche two [Member] Paradigm Spine [Member]	Oct. 31, 2013 Tranche three [Member] Durata [Member]
Accounts Notes And Loans Receivable [Line Items]
Financing receivable, gross										$ 0						$ 40,000,000		$ 15,000,000	$ 25,000,000		$ 35,000,000		$ 50,000,000			$ 2,300,000	$ 150,000,000	$ 7,500,000	$ 50,200,000	$ 10,000,000	$ 35,000,000			$ 20,000,000					$ 40,000,000				$ 1,300,000													$ 15,000,000		$ 30,000,000
Investee company financing				2,500,000
Number of payments to be received																										2
Periodic contractual payments																									1,200,000
First minimum payment																									1,200,000
Second minimum payment																								1,200,000
Financing Receivable, Modifications, Pre-Modification Recorded Investment																																									33,700,000												1,300,000	9,100,000
Financing receivable, modification, cost as a component of interest and other income, net								2,500,000
Financing Receivable, Net							53,939,820
Term of receivable (in Duration)																												2 years																		8 years
Royalty rate on AxoGen net revenues (in percent)																																														9.95%
Guaranteed quarterly minimum payment-low																																														1.3
Guaranteed quarterly minimum payment-high																																														2,500,000
Interest rate of note receivable (in Percent)								5.00%								15.50%			14.00%		15.50%		13.00%				13.00%	10.00%		12.00%				12.00%								13.50%		14.00%											12.75%	13.50%
Reduction in royalty rate (in percent)																																																				50.00%
Repayment of notes receivable				0	16,779,000					7,500,000	5,000,000
Financing receivable, prepayment fee												0.01
Credit agreement, stated interest rate (in Percent)																																							5.00%
Proceeds received under remedies available for borrower's breach of terms credit agreement																																					8,100,000
Amount company has agreed to advance under agreement									55,000,000							60,000,000	70,000,000			50,000,000		75,000,000										40,000,000				7,900,000		8,700,000							20,000,000												12,500,000
Financing Receivable, Modifications, Post-Modification Recorded Investment																																			44,100,000
Forbearance period under terms of credit agreement (in Duration)																																				120 days
Letter of credit extended																																								20,000,000
Term of royalty agreement (in Duration)																																														8 years
Total consideration paid to AxoGen for the royalty rights																																														20,800,000
Initial interim funding for royalty rights																																														1,800,000
Internal rate of return (in percent)																																														32.50%
fair value change of control																																															1,200,000		1,200,000		1,100,000
Embedded Derivative, Gain (Loss) on Embedded Derivative, Net																																															100,000	400,000	100,000	400,000
Investment Owned, Balance, Shares															1,166,666
Share Price						$ 7.97									$ 3.00
Investment Owned, at Cost															3,500,000
Investment Owned, at Fair Value														3,200,000
Unrealized Gain (Loss) on Investments			1,129,000	(167,000)									300,000
Maximum amount of additional funds, upon attainment of milestones																																	20,000,000
Debt Instrument, Date of First Required Payment																Dec. 31, 2016
Period after occurence of milestone, additional funding available [months]	9 months
Low end of amount company has agreed to advance under credit agreement																							6,250,000
Fair value of collateral supporting note receivable							$ 50,200,000
Period over which revenue is expected for valuation (in years)		15 years		15 years
Securitization of notes receivable from first approved product (in percent)																											100.00%
Securitization of notes receivable from second approved product (in percent)																											10.00%